Silence Therapeutics allowed another patent

Silence Therapeutics announced what it called a “further step” in the expansion of its chemical modification patent estate on Monday, with the US Patent and Trademark Office issuing a notice of allowance for US patent application 15/589971.

The AIM-traded company said it made the relevant payment of grant fees, and normal practice is that the granted patent will now be issued by the office.

It said the allowed claims of the patent application provided Silence with further protection for its innovative chemical modification technology in the US.

The Silence board said it believed the allowed claims were relevant to third-party medicines in ongoing clinical trials.

“In allowing this additional patent application for grant, the US Patent and Trademark Office has continued to uphold the validity of our expanding US patent estate,” said Silence chief executive officer Ali Mortazavi/

“We continue to believe that several third party late‐stage clinical RNAi candidates require licences under our patent portfolio.”